Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 20/20 | 0.86 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.80 |
| ▸ | MLNR | O43193 | 1/20 | 0.80 |
| ▸ | KDM1A | O60341 | 1/20 | 0.80 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.80 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.80 |
| ▸ | INSR | P06213 | 1/20 | 0.80 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.80 |
| ▸ | HTR1A | P08908 | 1/20 | 0.80 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.80 |
| ▸ | DRD2 | P14416 | 1/20 | 0.80 |
| ▸ | NQO2 | P16083 | 1/20 | 0.80 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.80 |
| ▸ | DRD1 | P21728 | 1/20 | 0.80 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.80 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.80 |
| ▸ | HTR2A | P28223 | 1/20 | 0.80 |
| ▸ | HTR2C | P28335 | 1/20 | 0.80 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.80 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Befotertinib SCHEMBL19337178 | 1.00 | EGFR (0.86) | EGFRKCNH2MLNRKDM1AABCB11 | |
| Befotertinib SCHEMBL30595515 | 1.00 | EGFR (0.86) | EGFRKCNH2MLNRKDM1AABCB11 | |
| Befotertinib SCHEMBL30354045 | 0.97 | EGFR (0.82) | EGFRKCNH2MLNRKDM1AABCB11 | |
| SCHEMBL19337200 | 0.95 | EGFR (0.84) | EGFRKCNH2MLNRKDM1AABCB11 | |
| SCHEMBL17553693 | 0.93 | EGFR (0.91) | EGFRKCNH2MLNRKDM1AABCB11 | |
| SCHEMBL17683310 | 0.93 | EGFR (1.00) | EGFRKCNH2MLNRKDM1AABCB11 | |
| SCHEMBL26554675 | 0.92 | EGFR (0.73) | EGFRKCNH2MLNRKDM1AABCB11 | |
| SCHEMBL22968448 | 0.92 | EGFR (0.90) | EGFRKCNH2MLNRKDM1AABCB11 | |
| SCHEMBL28412579 | 0.92 | EGFR (0.91) | EGFRKCNH2MLNRKDM1AABCB11 | |
| SCHEMBL28409356 | 0.92 | EGFR (0.91) | EGFRKCNH2MLNRKDM1AABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026103823-A1 | COMBINATION OF RAS INHIBITOR AND EGFR INHIBITOR AND USE THEREOF | 广州嘉越医药科技有限公司 | 2026-05-21 | — | — | WO | claimed |
| CN-122028932-A | Use of bispecific antibody in preparation of medicine for treating cancer | 上海翰森生物医药科技有限公司 | 2026-05-12 | — | — | CN | claimed |
| WO-2026086880-A1 | PHARMACEUTICAL COMPOSITION OF EGFR INHIBITOR AND USE THEREOF | 泰州红云制药有限公司 | 2026-04-30 | — | — | WO | claimed |
| US-20260021149-A1 | METHOD FOR TREATMENT OF TUMOR BY USING RECOMBINANT ONCOLYTIC VIRUS IN COMBINATION WITH SMALL-MOLECULE ANTICANCER DRUG | JOINT BIOSCIENCES SH LTD (CN) | 2026-01-22 | — | — | US | claimed |
| US-20250188171-A1 | COMBINATION THERAPY INCLUDING ANTIBODIES THAT BIND EGFR AND CMET | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2025-06-12 | — | — | US | claimed |
| US-20250179193-A1 | TREATMENT WITH AN ANTIBODY THAT BINDS EGFR AND CMET | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2025-06-05 | — | — | US | claimed |
| CN-120078896-A | Combination therapy comprising antibodies that bind EGFR to cMET | 美勒斯公司 | 2025-06-03 | — | — | CN | claimed |
| CN-120058955-A | Treatment with antibodies that bind EGFR and cMET | 美勒斯公司 | 2025-05-30 | — | — | CN | claimed |
| WO-2025105961-A1 | COMBINATION THERAPY INCLUDING ANTIBODIES THAT BIND EGFR AND cMET. | MERUS N.V. (NL) | 2025-05-22 | — | — | WO | claimed |
| WO-2025067492-A1 | USE OF BISPECIFIC ANTIBODY IN PREPARATION OF DRUG FOR TREATING CANCERS | 上海翰森生物医药科技有限公司 | 2025-04-03 | — | — | WO | claimed |
| EP-4490190-A1 | TREATMENT WITH AN ANTIBODY THAT BINDS EGFR AND CMET | Merus N.V. (NL) | 2025-01-15 | — | — | EP | claimed |
| CN-119278214-A | Treatment with antibodies that bind EGFR and cMET | 美勒斯公司 | 2025-01-07 | — | — | CN | claimed |
| CN-118974088-A | Combination therapy comprising antibodies that bind EGFR to cMET | 美勒斯公司 | 2024-11-15 | — | — | CN | claimed |
| EP-4424310-A1 | ANTI-TUMOR PHARMACEUTICAL COMPOSITION COMPRISING AZVUDINE AND AN EGFR/TKI INHIBITOR | Henan Genuine Biotech Co., Ltd. (CN) | 2024-09-04 | — | — | EP | claimed |
| US-20240108633-A1 | METHOD FOR PREVENTING OR TREATING DISEASE OR CONDITION ASSOCIATED WITH ANTITUMOR AGENT | ONQUALITY PHARMACEUTICALS CHINA LTD. (CN) | 2024-04-04 | — | — | US | claimed |
| US-11878028-B1 | Anti-tumor pharmaceutical composition comprising azvudine | HENAN GENUINE BIOTECH CO., LTD. (CN) | 2024-01-23 | — | — | US | claimed |
| WO-2023172133-A1 | COMBINATION THERAPY INCLUDING ANTIBODIES THAT BIND EGFR AND CMET | MERUS N.V. (NL) | 2023-09-14 | — | — | WO | claimed |
| WO-2023172134-A1 | TREATMENT WITH AN ANTIBODY THAT BINDS EGFR AND CMET. | MERUS N.V. (NL) | 2023-09-14 | — | — | WO | claimed |
| CN-116710141-A | Methods for preventing or treating antitumor agent-related diseases or conditions | 上海岸阔医药科技有限公司 | 2023-09-05 | — | — | CN | claimed |
| WO-2022143628-A1 | METHOD FOR PREVENTING OR TREATING DISEASE OR CONDITION ASSOCIATED WITH ANTITUMOR AGENT | 上海岸阔医药科技有限公司 | 2022-07-07 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260021149-A1 | METHOD FOR TREATMENT OF TUMOR BY USING RECOMBINANT ONCOLYTIC VIRUS IN COMBINATION WITH SMALL-MOLECULE ANTICANCER DRUG | ERBB2, BTK, ERBB3 | EGFR 5/4885KCNH2 3736/4885MLNR 1419/4885 |
| US-20240108633-A1 | METHOD FOR PREVENTING OR TREATING DISEASE OR CONDITION ASSOCIATED WITH ANTITUMOR AGENT | JAK2, JAK1, JAK3 | EGFR 439/4885KCNH2 347/4885MLNR 692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.